Literature DB >> 16048964

TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.

Cécile L Tremblay1, Françoise Giguel, Yongbiao Guan, Ting-Chao Chou, Katsunori Takashima, Martin S Hirsch.   

Abstract

TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16048964      PMCID： PMC1196290          DOI： 10.1128/AAC.49.8.3483-3485.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.

Authors:  C L Tremblay; C Kollmann; F Giguel; T C Chou; M S Hirsch
Journal:  J Acquir Immune Defic Syndr       Date:  2000-10-01       Impact factor: 3.731

2.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

Review 3.  Effects of HIV-1 entry inhibitors in combination.

Authors:  Cecile Tremblay
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

4.  Viral entry denied.

Authors:  Robert W Doms
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

5.  Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.

Authors:  Katsunori Takashima; Hiroshi Miyake; Naoyuki Kanzaki; Yoshihiko Tagawa; Xin Wang; Yoshihiro Sugihara; Yuji Iizawa; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

7.  In vivo antagonism with zidovudine plus stavudine combination therapy.

Authors:  D V Havlir; C Tierney; G H Friedland; R B Pollard; L Smeaton; J P Sommadossi; L Fox; H Kessler; K H Fife; D D Richman
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

8.  Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.

Authors:  Cécile L Tremblay; Françoise Giguel; Christopher Kollmann; Yongbiao Guan; Ting-Chao Chou; Bahige M Baroudy; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

9.  Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

Authors:  Patrick G Yeni; Scott M Hammer; Martin S Hirsch; Michael S Saag; Mauro Schechter; Charles C J Carpenter; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

10.  Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.

Authors:  Cécile L Tremblay; Danielle L Poulin; Jennifer L Hicks; Subajini Selliah; Annie Chamberland; Françoise Giguel; Christopher S Kollmann; Ting Chao Chou; Huajin Dong; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191
View more
  12 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

Review 3.  Targeting CCR5 for anti-HIV research.

Authors:  W-G Gu; X-Q Chen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-11       Impact factor: 3.267

Review 4.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

5.  Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.

Authors:  Katsunori Takashima; Hiroshi Miyake; Naoyuki Kanzaki; Yoshihiko Tagawa; Xin Wang; Yoshihiro Sugihara; Yuji Iizawa; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.

Authors:  Victoria A Johnson; Yoninah S Cramer; Susan L Rosenkranz; Stephen Becker; Karin L Klingman; Beatrice Kallungal; Eoin Coakley; Edward P Acosta; Gary Calandra; Michael S Saag
Journal:  AIDS Res Hum Retroviruses       Date:  2019-06-18       Impact factor: 2.205

Review 7.  Closing the door to human immunodeficiency virus.

Authors:  Yuanxi Kang; Jia Guo; Zhiwei Chen
Journal:  Protein Cell       Date:  2013-03-12       Impact factor: 14.870

8.  Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface.

Authors:  Adel A Rashad; Li-Rui Song; Andrew P Holmes; Kriti Acharya; Shiyu Zhang; Zhi-Long Wang; Ebony Gary; Xin Xie; Vanessa Pirrone; Michele A Kutzler; Ya-Qiu Long; Irwin Chaiken
Journal:  J Med Chem       Date:  2018-06-01       Impact factor: 7.446

9.  Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.

Authors:  Hirotomo Nakata; Seth M Steinberg; Yasuhiro Koh; Kenji Maeda; Yoshikazu Takaoka; Hirokazu Tamamura; Nobutaka Fujii; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 10.  Chemokines as possible targets in modulation of the secondary damage after acute spinal cord injury: a review.

Authors:  Peter Gál; Petra Kravcuková; Michal Mokrý; Darina Kluchová
Journal:  Cell Mol Neurobiol       Date:  2009-04-11       Impact factor: 5.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.